Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model. World J Hepatol 2021; 13(5): 543-556 [PMID: 34131469 DOI: 10.4254/wjh.v13.i5.543]
Corresponding Author of This Article
Yazen Alnouti, PhD, Professor, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 42nd and Emile, Omaha, NE 68198-6025, United States. yalnouti@unmc.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2021; 13(5): 543-556 Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.543
Table 1 Patient population characteristics
Patients
Death
Liver transplant
n
257
27
25
Gender
Male
136
21
17
Female
121
6
8
Age (yr)
mean ± SE
52.2 ± 0.71
55.9 ± 1.88
52.9 ± 2.1
Body mass index
mean ± SE
30.7 ± 0.45
29.65 ± 1.19
29.11 ± 0.45
Race
White
217
26
24
Black
11
0
0
Asian
7
0
0
Hispanic
4
0
1
Others
18
1
0
Non-BA parameters (mean ± SE)
Creatinine (mg/dL)
1.02 ± 0.09
Albumin (g/dL)
3.53 ± 0.04
INR
1.19 ± 0.02
Protime (s)
12.01 ± 0.42
AST (U/L)
59.9 ± 4.07
ALT (U/L)
54.9 ± 4.26
Bilirubin (mg/dL)
1.75 ± 0.15
AST/ALT
1.28 ± 0.04
MELD
10.6 ± 0.34
APRI
1.15 ± 0.11
Table 2 Multivariate Cox regression analysis for death prediction
BA indices (%) and non-BA parameters
B-value (regression coefficient)
Standard error
P value
Hazard ratio: Exp (B)
1 unit change
10% change
20% change
The BAS model
%CDCA
0.039
0.010
0.000
1.040
1.159
1.344
%Tri-OH
0.052
0.016
0.001
1.053
1.069
1.142
The non-BAS model
AST/ALT
1.236
0.303
0.000
3.442
1.165
1.357
Table 3 Receiver operating characteristics analysis of bile-acids score, non- bile-acids score, and models for end stage liver diseases for death prediction
Models
AUC (5-yr)
AUC (3-yr)
(Cutoff value; sensitivity, specificity)
BAS
0.740
0.761
(2.71; 74, 68)
non-BAS
0.653
0.664
(1.72; 67, 66)
MELD
0.683
0.715
(10; 62, 64)
Table 4 Estimated survival probability [S0 (t)] for death prediction
t (mo)
5
7
14
24
36
60
76
The BAS
S0 (t)
0.993
0.985
0.971
0.948
0.934
0.916
0.901
The non-BAS
S0 (t)
0.989
0.978
0.958
0.924
0.902
0.876
0.855
Table 5 Kaplan-Meier analysis for survival
Cutoff
Total n
n of events
Estimated mean (mo)
Standard error
95%CI
BAS
Median cutoff of 2.19
Low risk < 2.19
128
4
81.68
1.14
79.44-83.93
High risk > 2.19
129
23
70.72
2.5
65.81-75.62
Non-BAS
Median cutoff of 1.44
Low risk < 1.44
118
9
78.68
1.70
75.34-82.02
High risk > 1.44
139
18
73.97
2.21
69.64-78.29
MELD
Median cutoff of 11
Low risk < 11
133
11
78.06
1.71
74.71-81.42
High risk > 11
124
16
73.91
2.35
69.29-78.52
Citation: Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model. World J Hepatol 2021; 13(5): 543-556